Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7516 |
Intermediate Similarity |
NPD2791 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD7735 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD4871 |
Phase 2 |
0.733 |
Intermediate Similarity |
NPD5923 |
Phase 1 |
0.7296 |
Intermediate Similarity |
NPD4430 |
Phase 2 |
0.7278 |
Intermediate Similarity |
NPD3363 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD5042 |
Phase 1 |
0.7239 |
Intermediate Similarity |
NPD5546 |
Clinical (unspecified phase) |
0.7191 |
Intermediate Similarity |
NPD6557 |
Phase 2 |
0.7188 |
Intermediate Similarity |
NPD6301 |
Phase 2 |
0.7182 |
Intermediate Similarity |
NPD6022 |
Clinical (unspecified phase) |
0.7127 |
Intermediate Similarity |
NPD3439 |
Approved |
0.7069 |
Intermediate Similarity |
NPD5078 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD1594 |
Phase 3 |
0.7051 |
Intermediate Similarity |
NPD1595 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6887 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD6707 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD3277 |
Phase 3 |
0.6951 |
Remote Similarity |
NPD5839 |
Clinical (unspecified phase) |
0.6941 |
Remote Similarity |
NPD4485 |
Approved |
0.6933 |
Remote Similarity |
NPD2387 |
Approved |
0.6914 |
Remote Similarity |
NPD1165 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD1919 |
Approved |
0.6879 |
Remote Similarity |
NPD1920 |
Approved |
0.6867 |
Remote Similarity |
NPD1664 |
Clinical (unspecified phase) |
0.6831 |
Remote Similarity |
NPD4515 |
Suspended |
0.6829 |
Remote Similarity |
NPD3016 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD1001 |
Discontinued |
0.6805 |
Remote Similarity |
NPD2603 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD478 |
Approved |
0.6747 |
Remote Similarity |
NPD3278 |
Clinical (unspecified phase) |
0.6746 |
Remote Similarity |
NPD2882 |
Phase 1 |
0.6727 |
Remote Similarity |
NPD6506 |
Clinical (unspecified phase) |
0.6725 |
Remote Similarity |
NPD2469 |
Approved |
0.6725 |
Remote Similarity |
NPD2468 |
Approved |
0.6725 |
Remote Similarity |
NPD6395 |
Phase 2 |
0.6725 |
Remote Similarity |
NPD6396 |
Clinical (unspecified phase) |
0.6721 |
Remote Similarity |
NPD2814 |
Clinical (unspecified phase) |
0.6704 |
Remote Similarity |
NPD8022 |
Clinical (unspecified phase) |
0.6703 |
Remote Similarity |
NPD4334 |
Discontinued |
0.6686 |
Remote Similarity |
NPD1861 |
Discovery |
0.6685 |
Remote Similarity |
NPD6879 |
Phase 2 |
0.6685 |
Remote Similarity |
NPD6878 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD3487 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD4432 |
Discontinued |
0.6667 |
Remote Similarity |
NPD3321 |
Discontinued |
0.6667 |
Remote Similarity |
NPD5423 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD3864 |
Clinical (unspecified phase) |
0.6649 |
Remote Similarity |
NPD6141 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD7599 |
Phase 2 |
0.6632 |
Remote Similarity |
NPD5515 |
Phase 2 |
0.6629 |
Remote Similarity |
NPD3789 |
Approved |
0.6629 |
Remote Similarity |
NPD3883 |
Clinical (unspecified phase) |
0.6624 |
Remote Similarity |
NPD2146 |
Clinical (unspecified phase) |
0.6613 |
Remote Similarity |
NPD6965 |
Clinical (unspecified phase) |
0.6611 |
Remote Similarity |
NPD4020 |
Clinical (unspecified phase) |
0.6609 |
Remote Similarity |
NPD7600 |
Phase 2 |
0.6609 |
Remote Similarity |
NPD5989 |
Phase 1 |
0.6607 |
Remote Similarity |
NPD1886 |
Approved |
0.6606 |
Remote Similarity |
NPD1908 |
Phase 2 |
0.6596 |
Remote Similarity |
NPD3406 |
Suspended |
0.6588 |
Remote Similarity |
NPD6575 |
Clinical (unspecified phase) |
0.6582 |
Remote Similarity |
NPD995 |
Clinical (unspecified phase) |
0.6552 |
Remote Similarity |
NPD6060 |
Clinical (unspecified phase) |
0.6552 |
Remote Similarity |
NPD4514 |
Approved |
0.6543 |
Remote Similarity |
NPD2470 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD3824 |
Phase 1 |
0.6532 |
Remote Similarity |
NPD7091 |
Discontinued |
0.6524 |
Remote Similarity |
NPD8025 |
Phase 2 |
0.6522 |
Remote Similarity |
NPD1316 |
Discontinued |
0.651 |
Remote Similarity |
NPD5856 |
Discontinued |
0.6509 |
Remote Similarity |
NPD7441 |
Clinical (unspecified phase) |
0.6508 |
Remote Similarity |
NPD4315 |
Phase 2 |
0.6506 |
Remote Similarity |
NPD4168 |
Approved |
0.6503 |
Remote Similarity |
NPD1883 |
Approved |
0.6503 |
Remote Similarity |
NPD1998 |
Approved |
0.6497 |
Remote Similarity |
NPD7591 |
Clinical (unspecified phase) |
0.6491 |
Remote Similarity |
NPD1865 |
Approved |
0.6485 |
Remote Similarity |
NPD1870 |
Approved |
0.6485 |
Remote Similarity |
NPD3605 |
Approved |
0.6485 |
Remote Similarity |
NPD3068 |
Approved |
0.6484 |
Remote Similarity |
NPD3793 |
Phase 3 |
0.6477 |
Remote Similarity |
NPD5551 |
Clinical (unspecified phase) |
0.6474 |
Remote Similarity |
NPD3403 |
Clinical (unspecified phase) |
0.6474 |
Remote Similarity |
NPD3631 |
Phase 3 |
0.6474 |
Remote Similarity |
NPD4539 |
Phase 1 |
0.6471 |
Remote Similarity |
NPD5942 |
Approved |
0.6471 |
Remote Similarity |
NPD8103 |
Clinical (unspecified phase) |
0.6471 |
Remote Similarity |
NPD5941 |
Approved |
0.6468 |
Remote Similarity |
NPD7616 |
Discontinued |
0.6467 |
Remote Similarity |
NPD4204 |
Approved |
0.6467 |
Remote Similarity |
NPD4203 |
Approved |
0.6464 |
Remote Similarity |
NPD5153 |
Clinical (unspecified phase) |
0.6464 |
Remote Similarity |
NPD6316 |
Clinical (unspecified phase) |
0.6463 |
Remote Similarity |
NPD477 |
Phase 1 |
0.6456 |
Remote Similarity |
NPD2840 |
Approved |
0.6453 |
Remote Similarity |
NPD6476 |
Clinical (unspecified phase) |
0.6453 |
Remote Similarity |
NPD6158 |
Phase 2 |
0.6453 |
Remote Similarity |
NPD5663 |
Discontinued |
0.645 |
Remote Similarity |
NPD4351 |
Clinical (unspecified phase) |
0.6447 |
Remote Similarity |
NPD4901 |
Clinical (unspecified phase) |
0.6447 |
Remote Similarity |
NPD3123 |
Discovery |
0.6444 |
Remote Similarity |
NPD4150 |
Clinical (unspecified phase) |
0.6438 |
Remote Similarity |
NPD1271 |
Clinical (unspecified phase) |
0.6437 |
Remote Similarity |
NPD2527 |
Approved |
0.6436 |
Remote Similarity |
NPD7855 |
Clinical (unspecified phase) |
0.6429 |
Remote Similarity |
NPD3802 |
Phase 3 |
0.6429 |
Remote Similarity |
NPD2210 |
Approved |
0.6429 |
Remote Similarity |
NPD2212 |
Approved |
0.6424 |
Remote Similarity |
NPD5631 |
Phase 3 |
0.6421 |
Remote Similarity |
NPD5214 |
Phase 2 |
0.6419 |
Remote Similarity |
NPD1539 |
Approved |
0.6418 |
Remote Similarity |
NPD7225 |
Discontinued |
0.6413 |
Remote Similarity |
NPD5445 |
Approved |
0.6409 |
Remote Similarity |
NPD1599 |
Approved |
0.6407 |
Remote Similarity |
NPD2578 |
Phase 3 |
0.6402 |
Remote Similarity |
NPD6136 |
Phase 2 |
0.64 |
Remote Similarity |
NPD5715 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD4670 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD4669 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD4671 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD4900 |
Clinical (unspecified phase) |
0.6393 |
Remote Similarity |
NPD4317 |
Approved |
0.6392 |
Remote Similarity |
NPD1324 |
Clinical (unspecified phase) |
0.6391 |
Remote Similarity |
NPD5595 |
Clinical (unspecified phase) |
0.6391 |
Remote Similarity |
NPD4711 |
Clinical (unspecified phase) |
0.6391 |
Remote Similarity |
NPD6017 |
Discontinued |
0.6386 |
Remote Similarity |
NPD1864 |
Clinical (unspecified phase) |
0.6386 |
Remote Similarity |
NPD1866 |
Approved |
0.6375 |
Remote Similarity |
NPD4895 |
Clinical (unspecified phase) |
0.6374 |
Remote Similarity |
NPD5881 |
Clinical (unspecified phase) |
0.6374 |
Remote Similarity |
NPD7662 |
Clinical (unspecified phase) |
0.6374 |
Remote Similarity |
NPD4682 |
Phase 2 |
0.6369 |
Remote Similarity |
NPD5024 |
Approved |
0.6369 |
Remote Similarity |
NPD3587 |
Clinical (unspecified phase) |
0.6368 |
Remote Similarity |
NPD3785 |
Clinical (unspecified phase) |
0.6364 |
Remote Similarity |
NPD6403 |
Clinical (unspecified phase) |
0.6364 |
Remote Similarity |
NPD5657 |
Phase 3 |
0.6358 |
Remote Similarity |
NPD3150 |
Approved |
0.6358 |
Remote Similarity |
NPD950 |
Clinical (unspecified phase) |
0.6358 |
Remote Similarity |
NPD2658 |
Approved |
0.6358 |
Remote Similarity |
NPD3306 |
Approved |
0.6358 |
Remote Similarity |
NPD3148 |
Approved |
0.6358 |
Remote Similarity |
NPD3147 |
Approved |
0.6358 |
Remote Similarity |
NPD3149 |
Approved |
0.6358 |
Remote Similarity |
NPD2659 |
Approved |
0.6358 |
Remote Similarity |
NPD6670 |
Clinical (unspecified phase) |
0.6349 |
Remote Similarity |
NPD6608 |
Clinical (unspecified phase) |
0.6348 |
Remote Similarity |
NPD5140 |
Approved |
0.6348 |
Remote Similarity |
NPD5138 |
Approved |
0.6347 |
Remote Similarity |
NPD3069 |
Approved |
0.6347 |
Remote Similarity |
NPD4451 |
Approved |
0.6347 |
Remote Similarity |
NPD4450 |
Approved |
0.6343 |
Remote Similarity |
NPD6855 |
Clinical (unspecified phase) |
0.6341 |
Remote Similarity |
NPD679 |
Approved |
0.6337 |
Remote Similarity |
NPD6078 |
Clinical (unspecified phase) |
0.6337 |
Remote Similarity |
NPD5748 |
Phase 2 |
0.6335 |
Remote Similarity |
NPD7569 |
Approved |
0.6335 |
Remote Similarity |
NPD7570 |
Approved |
0.6327 |
Remote Similarity |
NPD1065 |
Approved |
0.6327 |
Remote Similarity |
NPD1064 |
Approved |
0.6325 |
Remote Similarity |
NPD2733 |
Approved |
0.6324 |
Remote Similarity |
NPD6452 |
Discontinued |
0.6322 |
Remote Similarity |
NPD2732 |
Approved |
0.6321 |
Remote Similarity |
NPD6449 |
Clinical (unspecified phase) |
0.6319 |
Remote Similarity |
NPD3137 |
Clinical (unspecified phase) |
0.6319 |
Remote Similarity |
NPD6607 |
Clinical (unspecified phase) |
0.6316 |
Remote Similarity |
NPD5117 |
Phase 2 |
0.6307 |
Remote Similarity |
NPD212 |
Discontinued |
0.6302 |
Remote Similarity |
NPD6046 |
Clinical (unspecified phase) |
0.6301 |
Remote Similarity |
NPD2328 |
Phase 2 |
0.6291 |
Remote Similarity |
NPD1764 |
Approved |
0.6291 |
Remote Similarity |
NPD1762 |
Approved |
0.6289 |
Remote Similarity |
NPD3125 |
Approved |
0.6289 |
Remote Similarity |
NPD6320 |
Approved |
0.6289 |
Remote Similarity |
NPD4985 |
Clinical (unspecified phase) |
0.6287 |
Remote Similarity |
NPD2304 |
Approved |
0.6287 |
Remote Similarity |
NPD3276 |
Approved |
0.6286 |
Remote Similarity |
NPD2891 |
Approved |
0.6286 |
Remote Similarity |
NPD7072 |
Phase 2 |
0.6286 |
Remote Similarity |
NPD1397 |
Clinical (unspecified phase) |
0.6286 |
Remote Similarity |
NPD7463 |
Clinical (unspecified phase) |
0.6284 |
Remote Similarity |
NPD6492 |
Phase 2 |
0.6284 |
Remote Similarity |
NPD5966 |
Clinical (unspecified phase) |
0.628 |
Remote Similarity |
NPD1106 |
Discontinued |
0.6279 |
Remote Similarity |
NPD979 |
Approved |
0.6279 |
Remote Similarity |
NPD4942 |
Approved |
0.6279 |
Remote Similarity |
NPD4939 |
Clinical (unspecified phase) |
0.6278 |
Remote Similarity |
NPD2341 |
Discontinued |
0.6275 |
Remote Similarity |
NPD4897 |
Phase 2 |
0.6272 |
Remote Similarity |
NPD1625 |
Approved |
0.6271 |
Remote Similarity |
NPD6738 |
Phase 2 |
0.6271 |
Remote Similarity |
NPD6737 |
Phase 2 |
0.627 |
Remote Similarity |
NPD2826 |
Approved |
0.627 |
Remote Similarity |
NPD2827 |
Approved |
0.627 |
Remote Similarity |
NPD2825 |
Approved |
0.6267 |
Remote Similarity |
NPD2583 |
Phase 2 |
0.6266 |
Remote Similarity |
NPD3622 |
Clinical (unspecified phase) |
0.6266 |
Remote Similarity |
NPD3623 |
Clinical (unspecified phase) |
0.6265
|
Remote Similarity |
NPD4077 |
Clinical (unspecified phase) |